The Week

Thermo Fisher fell 1.35% this week to $613.78, while the S&P 500 added 0.09%, leaving the stock about 1.44 percentage points behind the benchmark. The week’s range was 3.81%. Monday opened at $614.38 and touched $620.715, but Tuesday sliced through to $599.52 and closed at $600.50. The stock then recovered through Wednesday to Friday, ending at $613.78, still below the prior week’s $622.18 close.

Key Events

Most of this week’s company-level news clustered around a healthcare conference and insider disclosures. On 1 September, CEO Marc Casper spoke at the Morgan Stanley Global Healthcare Conference. The next day, President and COO Gianluca Pettiti reported a share disposal worth about $3.24 million, alongside several routine Form 4 filings that were not material. On the industry side, CLSA said on 3 September that the global pharma supply chain is entering a decade-long restructuring, favouring platform leaders including Thermo Fisher and WuXi AppTec. Nykredit A S also disclosed the purchase of about 115,000 shares.

Analyst Ratings

Across 31 firms covering the stock, 19 rate it buy, 4 rate it overweight, 5 rate it hold, and 1 rates it underweight; 2 have no opinion and none rate it sell. The consensus recommendation is buy, with a target of $638.11, roughly 4.0% above the current share price. Targets range from $520 to $750, a wide spread. The stock ranks first within the life sciences tools and services industry, where the average firm is covered by 10 brokers and the total industry universe is 54 companies.

The Week Ahead

The macro calendar is heavy. On 10 September, US jobless claims, headline PPI and core PPI are due, alongside the 10-year Treasury auction’s yield and bid-to-cover ratio. The NFIB small business optimism index arrives on 8 September. No company earnings are scheduled for next week. The more relevant thread is whether the pharma supply chain restructuring narrative continues to build, and how the market digests this week’s insider selling disclosure.

In Short

The rating picture is supportive: most brokers rate it buy or overweight, and the consensus target sits above spot by about 4.0%. But the valuation is not cheap at a price-to-book of 4.3x, and the latest session’s flows show small-lot selling with no large-lot participation. The stock spent the week chopping around the $600 area. Whether it can reclaim the prior weekly close likely depends on next week’s macro data and the supply chain story.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.